Who
Steven B. Binder
Director
Company insider
Files Form 4 as: EVP Special Projects, MannKind.
In numbers
- Trades disclosed
- 96
- Buys
- 9
- Sells
- 16
- Bought
- $19K
- Sold
- $3.7M
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 16 May 2018
- Last trade
- 25 Sep 2026
- Last filed
- 28 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 25 Sep 2026filed 28 Sep 2026 | MNKD MannKindPharmaceuticals | SEC FORM 4 Sold | $128K39,051 at $3.29 | filing |
| 25 Sep 2026filed 28 Sep 2026 | MNKD MannKindPharmaceuticals | SEC FORM 4 Sold | $128K39,051 at $3.29 | filing |
| 10 Sep 2026filed 14 Sep 2026 | MNKD MannKindPharmaceuticals | SEC FORM 4 Sold | $128K33,558 at $3.81 | filing |
| 10 Sep 2026filed 14 Sep 2026 | MNKD MannKindPharmaceuticals | SEC FORM 4 Sold | $128K33,558 at $3.81 | filing |
| 7 Aug 2026filed 10 Aug 2026 | MNKD MannKindPharmaceuticals | SEC FORM 4 Sold | $159K39,051 at $4.06 | filing |
| 7 Aug 2026filed 10 Aug 2026 | MNKD MannKindPharmaceuticals | SEC FORM 4 Sold | $159K39,051 at $4.06 | filing |
| 17 Jul 2026filed 17 Jul 2026 | MNKD MannKindPharmaceuticals | SEC FORM 4 Sold | $213K52,485 at $4.06 | filing |
| 17 Jul 2026filed 17 Jul 2026 | MNKD MannKindPharmaceuticals | SEC FORM 4 Sold | $213K52,485 at $4.06 | filing |
| 15 Jul 2026filed 17 Jul 2026 | MNKD MannKindPharmaceuticals | SEC FORM 4 Code M | —93,790 at $0.00 | filing |
| 15 Jul 2026filed 17 Jul 2026 | MNKD MannKindPharmaceuticals | SEC FORM 4 Code F | $64K15,688 at $4.09 | filing |
| 15 Jul 2026filed 17 Jul 2026 | MNKD MannKindPharmaceuticals | SEC FORM 4 Code F | $17K4,073 at $4.09 | filing |
| 15 Jul 2026filed 17 Jul 2026 | MNKD MannKindoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —93,790 at $0.00 | filing |
| 15 Jul 2026filed 17 Jul 2026 | MNKD MannKindPharmaceuticals | SEC FORM 4 Code F | $19K4,634 at $4.09 | filing |
| 15 Jul 2026filed 17 Jul 2026 | MNKD MannKindoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —93,790 at $0.00 | filing |
| 15 Jul 2026filed 17 Jul 2026 | MNKD MannKindPharmaceuticals | SEC FORM 4 Code M | —93,790 at $0.00 | filing |
| 15 Jul 2026filed 17 Jul 2026 | MNKD MannKindPharmaceuticals | SEC FORM 4 Code F | $64K15,688 at $4.09 | filing |
| 15 Jul 2026filed 17 Jul 2026 | MNKD MannKindPharmaceuticals | SEC FORM 4 Code F | $17K4,073 at $4.09 | filing |
| 15 Jul 2026filed 17 Jul 2026 | MNKD MannKindPharmaceuticals | SEC FORM 4 Code F | $19K4,634 at $4.09 | filing |
| 20 May 2026filed 22 May 2026 | MNKD MannKindoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —82,781 at $0.00 | filing |
| 20 May 2026filed 22 May 2026 | MNKD MannKindoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —82,781 at $0.00 | filing |
News
MannKind (NASDAQ:MNKD) and Monte Rosa Therapeutics (NASDAQ:GLUE) Head-To-Head AnalysisMNKD · tickerreport.com · 22 Oct 2026Financial Analysis: MannKind (NASDAQ:MNKD) & Iovance Biotherapeutics (NASDAQ:IOVA)MNKD · dailypolitical.com · 22 Oct 2026Comparing MannKind (NASDAQ:MNKD) & Iovance Biotherapeutics (NASDAQ:IOVA)MNKD · tickerreport.com · 15 Oct 2026
0 headlines in the last 90 days name Steven B. Binder; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.